BPMC
Price
$128.20
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
8.29B
24 days until earnings call
NTLA
Price
$10.74
Change
+$0.01 (+0.09%)
Updated
Jul 3 closing price
Capitalization
1.11B
25 days until earnings call
Interact to see
Advertisement

BPMC vs NTLA

Header iconBPMC vs NTLA Comparison
Open Charts BPMC vs NTLABanner chart's image
Blueprint Medicines
Price$128.20
Change-$0.00 (-0.00%)
Volume$437
Capitalization8.29B
Intellia Therapeutics
Price$10.74
Change+$0.01 (+0.09%)
Volume$2.81M
Capitalization1.11B
BPMC vs NTLA Comparison Chart in %
Loading...
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BPMC vs. NTLA commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BPMC is a Hold and NTLA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (BPMC: $128.20 vs. NTLA: $10.74)
Brand notoriety: BPMC and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BPMC: 0% vs. NTLA: 58%
Market capitalization -- BPMC: $8.29B vs. NTLA: $1.11B
BPMC [@Biotechnology] is valued at $8.29B. NTLA’s [@Biotechnology] market capitalization is $1.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BPMC’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • BPMC’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than BPMC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BPMC’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • BPMC’s TA Score: 3 bullish, 6 bearish.
  • NTLA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than BPMC.

Price Growth

BPMC (@Biotechnology) experienced а +0.04% price change this week, while NTLA (@Biotechnology) price change was +11.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

BPMC is expected to report earnings on Oct 23, 2025.

NTLA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BPMC($8.29B) has a higher market cap than NTLA($1.11B). BPMC YTD gains are higher at: 46.985 vs. NTLA (-7.890). BPMC has higher annual earnings (EBITDA): -66.42M vs. NTLA (-530.8M). BPMC has more cash in the bank: 576M vs. NTLA (504M). NTLA has less debt than BPMC: NTLA (119M) vs BPMC (467M). BPMC has higher revenues than NTLA: BPMC (562M) vs NTLA (45.6M).
BPMCNTLABPMC / NTLA
Capitalization8.29B1.11B745%
EBITDA-66.42M-530.8M13%
Gain YTD46.985-7.890-595%
P/E RatioN/AN/A-
Revenue562M45.6M1,232%
Total Cash576M504M114%
Total Debt467M119M392%
FUNDAMENTALS RATINGS
BPMC vs NTLA: Fundamental Ratings
BPMC
NTLA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
56100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
4041
P/E GROWTH RATING
1..100
66100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (28) in the Biotechnology industry is somewhat better than the same rating for BPMC (81). This means that NTLA’s stock grew somewhat faster than BPMC’s over the last 12 months.

BPMC's Profit vs Risk Rating (56) in the Biotechnology industry is somewhat better than the same rating for NTLA (100). This means that BPMC’s stock grew somewhat faster than NTLA’s over the last 12 months.

BPMC's SMR Rating (96) in the Biotechnology industry is in the same range as NTLA (97). This means that BPMC’s stock grew similarly to NTLA’s over the last 12 months.

BPMC's Price Growth Rating (40) in the Biotechnology industry is in the same range as NTLA (41). This means that BPMC’s stock grew similarly to NTLA’s over the last 12 months.

BPMC's P/E Growth Rating (66) in the Biotechnology industry is somewhat better than the same rating for NTLA (100). This means that BPMC’s stock grew somewhat faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BPMCNTLA
RSI
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 4 days ago
85%
MACD
ODDS (%)
Bearish Trend 4 days ago
69%
Bullish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 4 days ago
79%
Advances
ODDS (%)
Bullish Trend 6 days ago
73%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
73%
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
65%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
66%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEEFX88.490.81
+0.92%
American Funds Fundamental Invs 529-F-3
CVKFX16.220.07
+0.43%
Victory Pioneer Disciplined Value R6
SWFCX16.450.05
+0.30%
Touchstone International Value C
PINRX15.570.03
+0.19%
Principal Diversified Intl R3
IHOSX22.500.04
+0.18%
Hartford International Opportunities R4

BPMC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BPMC has been loosely correlated with KYMR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BPMC jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BPMC
1D Price
Change %
BPMC100%
N/A
KYMR - BPMC
49%
Loosely correlated
+0.58%
VERA - BPMC
47%
Loosely correlated
N/A
NRIX - BPMC
45%
Loosely correlated
+2.33%
APLS - BPMC
44%
Loosely correlated
+2.47%
IDYA - BPMC
42%
Loosely correlated
+0.82%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+0.09%
VCYT - NTLA
69%
Closely correlated
N/A
CRSP - NTLA
66%
Closely correlated
+0.97%
BEAM - NTLA
65%
Loosely correlated
+0.65%
RXRX - NTLA
56%
Loosely correlated
+1.15%
ABCL - NTLA
55%
Loosely correlated
+1.33%
More